5-chloro-1,2,3,4-tetrahydroquinoxalin-2-one | 148010-70-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 5-chloro-1,2,3,4-tetrahydroquinoxalin-2-one
• 英文别名: 5-chloro-3,4-dihydro-1H-quinoxalin-2-one
• CAS: 148010-70-2
• 化学式: C₈H₇ClN₂O
• 分子量: 182.609
• InChiKey: MZCZOGGMZQMPTI-UHFFFAOYSA-N

物化性质

• 沸点：
  379.7±42.0 °C(Predicted)
• 密度：
  1.335±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  5-chloro-1,2,3,4-tetrahydroquinoxalin-2-one 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 6-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo<1,5-a>quinoxaline
  参考文献：
  名称：

  High-Affinity Partial Agonist Imidazo[1,5-a]quinoxaline Amides, Carbamates, and Ureas at the γ-Aminobutyric Acid A/Benzodiazepine Receptor Complex

  摘要：

  A series of imidazo[1,5-alpha]quinoxaline amides, carbamates, and ureas which have high affinity for the gamma-aminobutyric acid A/benzodiazepine receptor complex was developed. Compounds within this class have varying efficacies racing from antagonists to full agonists. However, most analogs were found to be partial agonists as indicated by [S-35]TBPS and Cl- current ratios. Many of these compounds were also effective in antagonizing metrazole-induced seizures in accordance with anticonvulsant and possible anxiolytic activity. Selected quinoxalines displayed limited benzodiazepine-type side effects such as ethanol potentiation and physical dependence in animal models. Dimethylamino urea 41 emerged as the most interesting analog, having a partial agonist profile in vitro while possessing useful activity in animal models of anxiety such as the Vogel and Geller assays. In accordance with its partial agonist profile, 41 was devoid of typical benzodiazepine side effects.

  DOI：

  10.1021/jm940765f
• 作为产物：
  描述：

  2,3-二氯硝基苯 在 镍 sodium tetrahydroborate 、 硫酸 、 一水合肼 、 N,N-二异丙基乙胺 、 sodium iodide 作用下， 以 四氢呋喃 、 乙醇 、 水 、 乙腈 为溶剂， 反应 129.5h， 生成 5-chloro-1,2,3,4-tetrahydroquinoxalin-2-one
  参考文献：
  名称：

  High-Affinity Partial Agonist Imidazo[1,5-a]quinoxaline Amides, Carbamates, and Ureas at the γ-Aminobutyric Acid A/Benzodiazepine Receptor Complex

  摘要：

  A series of imidazo[1,5-alpha]quinoxaline amides, carbamates, and ureas which have high affinity for the gamma-aminobutyric acid A/benzodiazepine receptor complex was developed. Compounds within this class have varying efficacies racing from antagonists to full agonists. However, most analogs were found to be partial agonists as indicated by [S-35]TBPS and Cl- current ratios. Many of these compounds were also effective in antagonizing metrazole-induced seizures in accordance with anticonvulsant and possible anxiolytic activity. Selected quinoxalines displayed limited benzodiazepine-type side effects such as ethanol potentiation and physical dependence in animal models. Dimethylamino urea 41 emerged as the most interesting analog, having a partial agonist profile in vitro while possessing useful activity in animal models of anxiety such as the Vogel and Geller assays. In accordance with its partial agonist profile, 41 was devoid of typical benzodiazepine side effects.

  DOI：

  10.1021/jm940765f

文献信息

• [EN] HETEROCYCLIC CONDENSED COMPOUNDS USEFUL AS ANTIDIURETIC AGENTS<br/>[FR] COMPOSES CONDENSES HETEROCYCLIQUES UTILISES EN TANT QU'ANTIDIURETIQUES
  申请人：FERRING BV

  公开号：WO2006018443A1

  公开（公告）日：2006-02-23

  The invention concerns compounds according to general formulae 1, wherein G1 is an amine. Compounds according to the invention are vasopressin V2 receptor agonists. Pharmaceutical compositions of the compounds are useful as antidiuretic agents.

  这项发明涉及通式1中的化合物，其中G1是胺基。根据该发明的化合物是抗利尿激素V2受体激动剂。这些化合物的药物组合物可用作抗利尿剂。
• Imidazo[1,5-A]quinoxalines
  申请人：The Upjohn Company

  公开号：US05541324A1

  公开（公告）日：1996-07-30

  An invention relating to Imidazo[1,5-a]quinoxalines (I) ##STR1## which do not contain an endocyclic carbonyl group and which are useful as anxiolytic and sedative/hypnotic agents.

  一种涉及咪唑并[1,5-a]喹喔啉(I)的发明，不含内环羰基，并且可用作抗焦虑和镇静/催眠剂。
• Design, Synthesis, and Biological Evaluation of Analogues of the Antitumor Agent, 2-{4-[(7-Chloro-2-quinoxalinyl)oxy]phenoxy}propionic Acid (XK469)
  作者：Stuart T. Hazeldine、Lisa Polin、Juiwanna Kushner、Jennifer Paluch、Kathryn White、Matthew Edelstein、Eduardo Palomino、Thomas H. Corbett、Jerome P. Horwitz

  DOI：10.1021/jm0005149

  日期：2001.5.1

  at the several sites comprising the A-ring of region I, were next ascertained. Thus, a halogen substituent, located at the 7-position of a 2-(4-[(2-quinoxalinyl)oxy]phenoxy)propionic acid, generated the most highly and broadly active antitumor agents. A methyl, methoxy, or an azido substituent at this site generated a much less active structure, whereas 5-, 6-, 8-chloro-, 6-, 7-nitro, and 7-amino derivatives

  2-（4-[（7-氯-2-喹喔啉基）氧基]苯氧基）丙酸（XK469）是我们实验室中评估的活性最高，最广泛的抗肿瘤药物之一，目前计划在2002年进入临床试验2001。XK469的作用机理尚待阐明。因此，通过合成XK469类似物和评估结构修饰对实体瘤活性的影响的综合程序，开始努力建立药效基团假说以描述活性位点的要求。制定的策略选择将二维母体结构分成三个区域：喹喔啉的I环A；二，对苯二酚连接器的联动；和III，乳酸部分-确定每个区域化学变化的体外和体内效果。XK469的A环未取代或B环3-氯-区域异构体均未显示抗肿瘤活性。接下来确定位于包括区域I的A环的几个位点的不同电负性的取代基的调节抗肿瘤作用。因此，位于2-（4-[（2-喹喔啉基）氧基]苯氧基）丙酸的7-位的卤素取代基产生了活性最高和最广泛的抗肿瘤剂。在该位点的甲基，甲氧基或叠氮基取代基产生的活性结构要低得多，而5-，6-，8-氯-，6-，
• Heterocyclic Condensed Compounds Useful as Antidiuretic Agents
  申请人：Pitt Gary Robert William

  公开号：US20080234250A1

  公开（公告）日：2008-09-25

  The invention concerns compounds according to general formulae 1, wherein G 1 is an amine. Compounds according to the invention are vasopressin V 2 receptor agonists. Pharmaceutical compositions of the compounds are useful as antidiuretic agents.

  该发明涉及一般式1中G1为胺基的化合物。根据该发明的化合物是利尿激素V2受体激动剂。该化合物的药物组成物作为抗利尿剂是有用的。
• Heterocyclic condensed compounds useful as antidiuretic agents
  申请人：Vantia Limited

  公开号：US08063038B2

  公开（公告）日：2011-11-22

  The invention concerns compounds according to general formulae 1, wherein G1 is an amine. Compounds according to the invention are vasopressin V2 receptor agonists. Pharmaceutical compositions of the compounds are useful as antidiuretic agents.

  本发明涉及一般式1中G1为胺基的化合物。本发明的化合物是加压素V2受体激动剂。所述化合物的制药组合物可用作抗利尿剂。